Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS OXYS-I trial of hepatic arterial infusion versus intravenous oxaliplatin in liver-dominant malignancies
2026-527509-39-01Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin in colorectal cancer liver metastasis (CRLM) and intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Dose-corrected intratumoral total platinum concentration difference. Planned start Oct 2026; status: authorised.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer liver metastasis (CRLM)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2026-527509-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527509-39-01.